nevirapine has been researched along with Delayed Effects, Prenatal Exposure in 6 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, neutropenia was no longer associated with antenatal exposure to HAART after 1 month of age." | 2.73 | Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. ( Bae, WH; Essex, M; Lockman, S; Onyait, K; Shapiro, RL; Smeaton, LM; Thior, I; Wester, C, 2008) |
| " Mice were dosed twice daily until PND 28." | 1.39 | Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in u ( , 2013) |
| " Nevirapine is well absorbed during labor, and sufficient drug for prophylaxis against perinatal transmission crosses the placenta if an oral dose is administered to the mother at least 1 hour before delivery." | 1.31 | Antiretroviral pharmacology in pregnant women and their newborns. ( Mirochnick, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, WH | 1 |
| Wester, C | 1 |
| Smeaton, LM | 1 |
| Shapiro, RL | 1 |
| Lockman, S | 1 |
| Onyait, K | 1 |
| Thior, I | 1 |
| Essex, M | 1 |
| Temmerman, M | 1 |
| Quaghebeur, A | 1 |
| Mwanyumba, F | 1 |
| Mandaliya, K | 1 |
| Urban, MF | 1 |
| Chersich, MF | 1 |
| Mirochnick, M | 1 |
1 trial available for nevirapine and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.
Topics: Alanine Transaminase; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active | 2008 |
5 other studies available for nevirapine and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in u
Topics: Animals; Animals, Genetically Modified; Animals, Newborn; Anti-HIV Agents; Body Weight; Chemistry, P | 2013 |
Toxicology and carcinogenesis studies of mixtures of 3'-azido-3'-deoxythymidine (AZT), lamivudine (3TC), nevirapine (NVP), and nelfinavir mesylate (NFV) (Cas Nos. 30516-87-1, 134678-17-4, 129618-40-2, 159989-65-8) in B6C3F1 Mice (transplacental exposure s
Topics: Administration, Oral; Animals; Anti-Retroviral Agents; DNA; Drug Therapy, Combination; Escherichia c | 2013 |
Mother-to-child HIV transmission in resource poor settings: how to improve coverage?
Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; HIV Infections; Humans; Infant, Newborn; | 2003 |
Dandy-Walker variant in an infant prenatally exposed to antiretroviral medication.
Topics: Adult; Anti-Retroviral Agents; Dandy-Walker Syndrome; Female; Heart Ventricles; HIV Infections; Huma | 2007 |
Antiretroviral pharmacology in pregnant women and their newborns.
Topics: Administration, Oral; Anti-HIV Agents; Delivery, Obstetric; Female; HIV Infections; Humans; Infant; | 2000 |